Bank of America, Jefferies Deliver Varied Buy and Hold Ratings on Key Stocks

TSURUHA Holdings shows notable trading metrics not highlighted in the summary: a 1-year high of 2,993.00 yen, a 1-year low of 1,889.00 yen, and an average daily trading volume of about 2.46 million shares.
Pfizer's quarterly results show revenue of $14.45 billion and net profit of $2.69 billion for the quarter ending March 29, alongside insider activity indicating negative sentiment with 15 insiders selling, including Jennifer B. Damico selling 2,000 shares for $51,400.
Bread Financial Holdings received corroborating sector support beyond Bank of America: UBS issued a Buy on Bread Financial, and Barclays upgraded the stock to a Hold on the same day; Bread Financial reported quarterly revenue of $1.21 billion and net profit of $181 million.
Befesa S.A. remains on Jefferies’ radar with a Buy rating and a €43 target, while the broader consensus sits at a Moderate Buy with an average target of €39.17.
JCDecaux SA continues to attract a Strong Buy consensus with an average target of €24.81, while Berenberg reiterates a Buy with a €28 target; current price closed near €21, with a 1-year high around €21.04 and a 1-year low around €14.12.
Bank of America Securities has kept its Buy rating on TSURUHA Holdings, a major Japanese pharmacy retailer, with a price target of ¥3,000, according to The Globe and Mail. The stock has traded between ¥1,889 and ¥2,993 over the past year, with an average daily volume of about 2.46 million shares — placing the current target just above the one-year high.
The move is part of a broader wave of analyst ratings across several sectors, with firms including Jefferies, Berenberg, and UBS all issuing or reaffirming positions on stocks in healthcare, outdoor advertising, and consumer finance.
Bank of America's ¥3,000 price target sits just above TSURUHA's one-year high of ¥2,993, according to The Globe and Mail. That means BofA sees almost no further upside at current levels — yet still calls it a Buy. The rating signals confidence in the retailer's long-term fundamentals rather than a near-term price pop.
TSURUHA Holdings operates a large chain of drugstores across Japan. High trading volume — around 2.46 million shares per day — shows strong investor interest. The stock's low of ¥1,889 earlier in the year means it has already surged nearly 58% from its bottom.
Pfizer sits at a crossroads of analyst opinion. Bank of America holds a Hold rating with a $26 target, while Jefferies rates the stock a Buy and JP Morgan also holds a Hold, according to Business Insider. The split reflects uncertainty after Pfizer posted quarterly revenue of $14.45 billion and net profit of $2.69 billion for the period ending March 29.
Insider activity adds another cautious note. Fifteen insiders have sold shares recently, including Jennifer B. Damico, who sold 2,000 shares for $51,400. Heavy insider selling often signals that those closest to the company see limited upside in the short term.
Bread Financial Holdings is drawing attention from multiple banks at once. Bank of America rates it a Buy with a $106 target. UBS also issued a Buy on the same day. Barclays upgraded the stock, though only to a Hold, according to Business Insider. Three firms moving on one stock the same day is unusual and points to a catalytic event.
The company reported quarterly revenue of $1.21 billion and net profit of $181 million. Those are solid numbers for a consumer finance firm. The BofA $106 target gives the stock meaningful implied upside depending on where shares are currently trading.
Two European names are also getting attention. Jefferies rates Befesa S.A. a Buy with a €43 price target. The broader analyst consensus sits at a Moderate Buy with an average target of €39.17 — still well above current levels. Befesa recycles steel dust and hazardous waste, making it a play on industrial sustainability.
JCDecaux SA, the outdoor advertising giant, earned a Buy reiteration from Berenberg with a €28 target. The stock closed near €21, just off its one-year high of €21.04. Its one-year low was €14.12, meaning shares have already climbed about 49% from the bottom. The broader consensus is a Strong Buy, with an average target of €24.81.
Publishers
16
Articles
1
Reach
17